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Radiation recall phenomenon is a tissue reaction that develops within a previously irradiated area, precipitated by
the subsequent administration of certain chemotherapeutic agents. It commonly affects the skin, but can also
involve internal organs with functional consequences. To our best knowledge, this phenomenon has never been
reported as a complication on the heart and should be consider as a potential cause of cardiotoxicity.Background
Radiation recall reaction (RRR) refers to an inflamma-
tory reaction within a previously treated radiation field.
The reaction occurs in response to the combined effect
of radiotherapy and a second precipitating agent, mainly
with chemotherapeutic drugs. We would like to describe
a case of RRR that involved the heart.Case presentation
We present a 56-year old man with a prior history of
adenocarcinoma of the lung with metastasis to cervical
lymph nodes and brain diagnosed in 2006. He was initially
treated with chemotherapy in 2006. Subsequently, he
required stereotactic radiation to the chest and cervical
lymph nodes with a total dose of 7000 CGy. Since his
initial therapies, he has received multiple chemother-
apy treatments including cisplatin, docetaxel, bevacizu-
mab, erlotinib, and gemcitabine. Most recently, he was
started on sorafenib.
Five month later, he presented with chest pain. No sig-
nificant electrocardiographic changes were present and his
troponin level was normal. An echocardiogram showed
mildly decreased left ventricular systolic function with an
ejection fraction of 45%. The anterior wall was hypokinetic
and there was a small pericardial effusion.
A coronary angiogram was performed which demon-
strated no significant coronary artery disease (Figure 1).
Cardiovascular magnetic resonance (CMR) was then
performed, which demonstrated increased signal onT2
weighted images in the basal and mid anterior wall, in-
dicative of edema (Figure 2A). Using late gadolinium* Correspondence: cmasri@uw.edu
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unless otherwise stated.enhancement (LGE) imaging, enhancement was identified
in the same portions of the basal and mid anterior wall
(Figure 2B).
A FDG-PET /CT performed 3 months prior to the pa-
tient’s clinical presentation of chest pain (about 2 months
into sorafenib therapy), revealed regional uptake of FDG
in the same the basal and mid anterior wall segments
(Figure 3A and B). These findings were new compared
to a FDG-PET/CT scan performed 2 years earlier (about
1 year after the initial radiation therapy) which had
showed no myocardial uptake of FDG (Figure 4A, B).
Whole body nuclear bone scan revealed a photopenic
area in the mid thorax (Figure 5), attributable to prior
radiation therapy.
Interestingly, the abnormal myocardial wall segments
demonstrated on FDG-PET/CT, echocardiography and
CMR also corresponded to the previously irradiated
area. Due to these findings, sorefanib was discontin-
ued. He had no recurrent chest pain.
Discussion
Radiation recall reaction (RRR) refers to an inflamma-
tory reaction within a previously treated radiation field.
The reaction occurs in response to the combined effect
of radiotherapy and a second precipitating agent. The
second precipitating agent has been observed mainly
with chemotherapeutic drugs. It can occur months or
even many years after irradiation, suggesting that the
mechanism may be different from radiosensitization [1].
Skin is the major site of radiation recall toxicity. But,
the phenomenon has also been described in other organs
including the lung, digestive tract, muscle, and central
nervous system. However, to the best of our knowledge
radiation recall toxicity has never been reported in the
heart.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Left coronary angiogram, showing the left anterior
descending artery (LAD) and left circumflex artery (LCX).
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onset chest pain in the setting of remote radiation ther-
apy and ongoing chemotherapy likely represents an in-
stance of radiation recall myocarditis. Features such as
acute onset reduced ejection fraction with regional wall
motion abnormalities, regional inflammation and edema
on FDG-PET/CT and T2 weighted CMR, and regional
enhancement on LGE-CMR may result from a variety of
causes, including ischemic heart disease. Our patient
underwent coronary angiography and had no evidence
of obstructive coronary disease. Other possibilities might
include infiltrative disease like cardiac sarcoidosis or
myocarditis [2]. However, it would be highly improbable
for our patient to develop de novo infectious myocarditisA
Figure 2 CMR short axis images of the mid left ventricle. T2-weighted
in the anterior and anteroseptal wall. Late gadolinium enhancement (B) (ar
T2-weighted imaging, suggesting edema or a combination of edema andor sarcoid in precisely the same anatomic distribution as
the previous radiation field.
We propose that the diagnosis of radiation recall reac-
tion myocarditis induced by chemotherapy is estab-
lished in our case by a history of chemotherapy after
thoracic radiotherapy, with CMR and FDG-PET/CT
showing evidence of inflammation in the irradiated
areas of the myocardium. When radiation therapy is
followed by chemotherapy, subclinical damage from
irradiation can be unmasked or potentiated and ultim-
ately manifest clinically as RRR.
Taxanes and anthracyclines have been reported to be
responsible for 20% and nearly 30% of radiation recall
reaction, respectively [3]. The inciting agents observed
in radiation recall phenomenon previously reported in-
cluded taxanes, anthracyclines, gemcitabine, etoposide,
vinorelbine and erlotinib [3-5]. Sorafenib is a small mol-
ecule tyrosine kinase inhibitor of vascular endothelial
growth factor (VEGF) and platelet-derived growth factor
(PDGF) receptors, increasingly used in advanced solid
organ treatment and it has recently been implied in this
phenomenon [6]. The range of chemotherapeutic drugs
associated with the phenomenon is diverse and no com-
mon features or characteristics of the drugs have been
identified. It is not clear whether RRR are a class effect
or related to the drug dose or regimen. Reactions have
occurred with a range of dosages of different drugs. The
mechanism of this phenomenon is not clear, though it
may be related to increased local vascular permeability
caused by radiotherapy. In our case, this phenomenon
was likely exacerbated by subsequent administration of
sorenafib and resultant endothelial dysfunction from
its inhibitory effects on VEGF receptor. The mechan-
ism is unknown but may involve impaired of the angio-
genesis leading to a decrease in the microvessels (a
process known as capillary rarefaction) or endothelialB
image (A) demonstrates bright myocardium (arrow) suggesting edema
row) corresponds with the territories of bright myocardium on
fibrosis.
A B
Figure 4 Whole-body FDG PET image in a fasting condition shows FDG accumulation in multiple prevascular, left hilar and subcarinal
lymph nodes. There is no myocardial uptake of FDG. Sagital image of fasting FDG-PET (A). Coronal image of fasting FDG-PET (B).
A B
Figure 3 Whole-body FDG PET image in fasting condition shows FDG accumulation in the submandibular region, mediastinal, and
right hilum lymph nodes and the heart involving basal and mid anterior wall (A). Short-axis image of fasting FDG-PET of the heart with
FDG accumulation in the anterior and anteroseptal wall (B).
Figure 5 Whole body nuclear bone scan revealed a photopenic area in the mid thorax.
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[7]. The reported time interval between radiation and
subsequent chemotherapy leading to RRR is variable
from days to years. Current treatment strategies include
the withdrawal of the causative agents and administration
of systemic steroids [8].Conclusion
Radiation recall phenomenon is a tissue reaction that
develops within a previously irradiated area, precipitated
by the subsequent administration of certain chemothera-
peutic agents. It commonly affects the skin, but can also
involve internal organs with functional consequences.
While undoubtedly rare and previously unreported, radi-
ation recall phenomenon should be considered as a po-
tential cause of cardiotoxicity in the appropriate context.Consent
This case report was approved by the IRB of University
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